Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
heat-inactivated Bifidobacterium bifidum SYN-HI-001
- Development stage
- Unknown
- Lead developer
- SYNformulas
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Heat-inactivated Bifidobacterium bifidum SYN-HI-001 (also known as HI-MIMBb75) is a non-viable, heat-killed postbiotic preparation of the probiotic strain Bifidobacterium bifidum MIMBb75. Developed by Synformulas GmbH, it is indicated for the treatment of irritable bowel syndrome (IBS). The mechanism of action involves the modulation of the gut microbiome and physical interaction with the intestinal epithelium, which helps to strengthen the gut barrier and reduce intestinal permeability. Unlike live probiotics, its beneficial effects are mediated independently of bacterial cell viability. Clinical data from a large-scale, multicenter, randomized, double-blind, placebo-controlled trial in Germany demonstrated that SYN-HI-001 significantly alleviates IBS symptoms, including abdominal pain, bloating, and urgency, with a safety profile comparable to placebo.
- Brand names
- Kijimea IBS Pro
- Other names
- heat-inactivated Bifidobacterium bifidum MIMBb75non-viable Bifidobacterium bifidum MIMBb75
Beyond the preview
Go deeper on heat-inactivated Bifidobacterium bifidum SYN-HI-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on heat-inactivated Bifidobacterium bifidum SYN-HI-001.